These authors contributed equally to this review.
The emerging era of pharmacogenomics: current successes, future potential, and challenges
Article first published online: 9 MAY 2014
© 2014 The Authors. Clinical Genetics published by JohnWiley & Sons A/S. Published by JohnWiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Special Issue: Personalized Medicine and Clinical Genetics
Volume 86, Issue 1, pages 21–28, July 2014
How to Cite
Lee, J.W., Aminkeng, F., Bhavsar, A.P., Shaw, K., Carleton, B.C., Hayden, M.R. and Ross, C.J.D. (2014), The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clinical Genetics, 86: 21–28. doi: 10.1111/cge.12392
The authors have applied for patents based upon some of the work related to predictive markers of ADRs to cisplatin and anthracyclines described in this review. The funding agencies had no role in study design; collection, analysis and interpretation of data; writing of the report; or the decision to submit the report for publication.
- Issue published online: 3 JUN 2014
- Article first published online: 9 MAY 2014
- Accepted manuscript online: 29 MAR 2014 08:35AM EST
- Manuscript Accepted: 27 MAR 2014
- Manuscript Revised: 24 MAR 2014
- Manuscript Received: 5 MAR 2014
- Canadian Institutes of Health Research (CIHR)
- Child and Family Research Institute (CFRI)
- Michael Smith Foundation for Health Research
- CIHR-Drug Safety and Effectiveness Cross-Disciplinary Training Program
- Canada Foundation for Innovation
- Genome British Columbia
- The University of British Columbia Faculty of Medicine
- The Canadian Gene Cure Foundation, C17 Research Network and Childhood Cancer Foundation
- adverse drug reactions;
The vast range of genetic diversity contributes to a wonderful array of human traits and characteristics. Unfortunately, a consequence of this genetic diversity is large variability in drug response between people, meaning that no single medication is safe and effective in everyone. The debilitating and sometimes deadly consequences of adverse drug reactions (ADRs) are a major and unmet problem of modern medicine. Pharmacogenomics can uncover associations between genetic variation and drug safety and has the potential to predict ADRs in individual patients. Here we review pharmacogenomic successes leading to changes in clinical practice, as well as clinical areas probably to be impacted by pharmacogenomics in the near future. We also discuss some of the challenges, and potential solutions, that remain for the implementation of pharmacogenomic testing into clinical practice for the significant improvement of drug safety.